UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES, INCLUDING WALDENSTROM MACROGLOBULINEMIA
HAEMATOLOGICA(2015)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要